Another mechanism of obeticholic acid in NASH treatment has been discovered that inhibits NLRP3 inflammasome in macrophage activation and suppresses lipid accumulation without the participation of the farnesoid X receptor (108). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.